Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies

Abstract

Musalula Sinkala et al. report that collectively, specific mutations of genes in 5 MAPK pathways are associated with worse patient survival. They identify gene components that are pharmacologically vulnerable to pathway inhibitors in cancer cell models, suggesting potential clinical applications of these findings.